Hyderabad-based Natco Pharma has launched the first generic version of Gilead's Sofosbuvir in Nepal.

Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, under the brand name Epclusa.

Natco will market Sofosbuvir under the name Velpanat as a single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Read the Business Standard coverage